Long-duration mild hypothermia: a multicentre severe TBI trial

“Long-duration mild hypothermia improves favourable outcomes in patients with severe TBI and malignant intracranial hypertension”—this is the key finding reported in the multicentre randomised controlled study on the safety and efficacy of long-duration mild hypothermia, published online on 29 January in the Lancet-family journal eClinicalMedicine.
Led by Jiyao Jiang, Chief Expert at Renji Hospital, Shanghai Jiao Tong University School of Medicine, and Director of the Shanghai Institute of Head Trauma, the study took eight years. It addressed an internationally important question about prolonged hypothermia, and the journal’s editor described it as exciting research.

Fourteen major Chinese TBI centres screened 2,946 acute patients and randomised 302 eligible severe cases to 35°C for five days or normothermia at 37°C. In patients with ICP above 30 mmHg, favourable outcomes were 60.82% with hypothermia and 42.71% with normothermia. However, outcomes did not significantly improve across all severe TBI patients. The source describes this as the first completed multicentre randomised trial of long-duration cooling in severe TBI, offering evidence for more targeted use.
China has hundreds of thousands of new TBI patients each year, and severe injury carries high mortality and disability, burdening families and society. Jiang’s team has pursued standardised care and evidence-based clinical research. Since 2008, it has led 13 Chinese guidelines and consensuses covering monitoring, surgery and medicines. In February 2019, Jiang’s Lancet Neurology cover series “Traumatic Brain Injury in China,” as sole corresponding author, described nearly two decades of injury characteristics, progress, gaps and priorities. In July 2020, another cover research article presented the Chinese registry cohort, again with Jiang as sole corresponding author. The current eClinicalMedicine publication reports the hypothermia trial. Former INTS President Andrew Maas congratulated the team by video, noting its value for severe TBI care.

Jiang stated that Chinese severe TBI care has reached levels comparable with developed European and US settings, but few Chinese studies have changed their guidelines or consensuses. He hopes more Chinese evidence will influence international guidelines and academic standing and improve standardised, precise treatment to reduce death and disability in China and globally.
Jiyao Jiang is corresponding author; Guoyi Gao of Shanghai First People’s Hospital is co-corresponding author. Renji’s Jiyuan Hui is first author; co-first authors are Junfeng Feng, Yue Tu, Director of Neurocritical Care at Beijing Chaoyang Integrated Traditional Chinese and Western Medicine Emergency Rescue Centre, and Weituo Zhang of the Clinical Research Centre, Shanghai Jiao Tong University School of Medicine. Funding came from the school’s first clinical research programme and Shanghai’s Plateau and Peak initiative.

Renji Hospital — renji1844. Select “Watching” to help more people see the report.
“长时程亚低温治疗能有效提高重型颅脑创伤伴有恶性颅高压病人的预后良好率”——这是《柳叶刀》子刊《临床医学》(《EClinicalMedicine》)杂志于1月29日在线发表《长时程亚低温治疗对重型颅脑创伤伴有恶性颅内压增高患者安全性和有效性的一项多中心、随机、对照研究》中的重要研究发现。
该项研究在上海交通大学医学院附属仁济医院首席专家、上海市颅脑创伤研究所所长江基尧教授的牵头组织下历时8年完成。研究结果回答了国际颅脑创伤领域极其关注的长时程亚低温治疗的安全性和有效性问题,被《临床医学》的主编认为是“激动人心的研究”。

该项研究在国内14家大型颅脑创伤中心开展,从2946例急性颅脑创伤病人中,筛选出符合研究条件的302例重型颅脑创伤病例并将其随机分为长时程亚低温组(35℃,5天)或常温组(37℃)。研究结果显示:长时程亚低温能显著提高颅内压大于30mmHg重型颅脑创伤病人预后良好率,亚低温组为60.82%、常温组为42.71%。但是,并不能显著改善所有重型颅脑创伤患者的预后。该研究是全球第一个完成的长时程低温治疗重型颅脑创伤病人的多中心临床随机对照研究,为临床精准采用亚低温治疗提供了新的临床证据。
中国颅脑创伤患者每年新增数十万人,重型颅脑创伤病人死残率高,给社会和家庭带来巨大损失和负担。江基尧教授带领中国颅脑创伤团队致力于中国颅脑创伤规范化救治技术和临床循证医学研究。2008年以来,牵头制定了13个中国颅脑创伤相关的脑监测技术、外科手术、药物应用等指南和专家共识;2019年2月,《柳叶刀神经病学》封面论文形式刊登他作为唯一通讯作者的《中国颅脑创伤》长篇系列报道,首次详细展示了近20年中国颅脑创伤的基本特征,全面展示了中国颅脑创伤临床救治和研究进步与不足以及努力方向;2020年7月,《柳叶刀神经病学》再次以封面论著形式发表他作为唯一通讯作者的中国颅脑创伤大数据注册队列研究成果。现在,柳叶刀子刊《EClinicalMedicine》在线发表他和他的团队关于中国低温临床研究成果。国际神经创伤协会前主席Andrew Maas教授通过视频祝贺中国长时程低温研究发表在柳叶刀子刊《EClinicalMedicine》,对于提高重型颅脑创伤治疗水平具有重要价值。

江基尧教授指出,中国的重型颅脑创伤临床救治水平已经赶上欧美发达国家。但是很少有中国临床研究证据改变欧美国家颅脑创伤救治《指南》、《专家共识》。他非常期待更多的中国临床循证医学研究证据能改变欧美国家和全球颅脑创伤救治指南,提高中国颅脑创伤在国际舞台上的学术地位。为进一步提高中国和全球颅脑创伤救治的规范化和精准化、降低重型颅脑创伤病人死残率做出更大贡献。
该论文通讯作者为上海交通大学医学院附属仁济医院江基尧教授、共同通讯作者是上海市第一人民医院高国一教授。论文第一作者是仁济医院惠纪元博士,共同第一作者是仁济医院冯军峰博士、北京朝阳中西医结合急诊抢救中心神经重症科涂悦主任和上海交通大学医学院临床研究中心张维拓博士。该项目得到上海交通大学医学院首批临床研究项目、上海市高原高峰计划资助。

仁济医院
-renji1844-
点个“在看”,让更多人看到